TY - JOUR
T1 - Thiazolidinedione therapy and breast cancer risk in diabetic women
T2 - A systematic review and meta-analysis
AU - Du, Rui
AU - Lin, Lin
AU - Cheng, Di
AU - Xu, Yu
AU - Xu, Min
AU - Chen, Yuhong
AU - Wang, Weiqing
AU - Bi, Yufang
AU - Li, Donghui
AU - Lu, Jieli
N1 - Funding Information:
This study was funded by the Ministry of Science and Technology of the People's Republic of China (2016YFC1305202, 2015BAI12B02 and 2015BAI12B14) and the National Natural Science Foundation of China (81370960 and 81670795). Jieli Lu was supported by Shuguang Program (15SG15) and Gaofeng Clinical Medicine Grant Support (20152202) from Shanghai Municipal Education Commission. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Funding Information:
Ministry of Science and Technology of the People's Republic of China, Grant/Award Numbers: 2016YFC1305202, 2015BAI12B02 and 2015BAI12B14; National Natural Science Foundation of China, Grant/Award Numbers: 81370960 and 81670795; Shanghai Municipal Education Commission, Grant/Award Numbers: 15SG15 and 20152202
Publisher Copyright:
Copyright © 2017 John Wiley & Sons, Ltd.
PY - 2018/2
Y1 - 2018/2
N2 - Rising experimental evidence suggests that thiazolidinediones (TZDs) exert a protective effect on breast cancer. However, studies concerning this issue were inconsistent and limited. Hence, we performed a meta-analysis with data from currently available studies to evaluate the effect of TZDs on breast cancer risk among diabetic women. We comprehensively searched for all pertinent studies addressing TZDs use and breast cancer risk published before January 1, 2016, in PubMed, Clinical Trials, and Cochrane Library. Data synthesis was performed in a random-effects model using Stata version 12.0 (Stata Corp, College Station, Texas). Fourteen independent studies were eventually selected in this meta-analysis, including 5 randomized controlled clinical trials (RCTs), 7 cohort studies, and 2 case-control studies. No significant associations of TZD use and risk of breast cancer were observed in the RCTs (pooled risk ratio [RR]: 0.77, 95% confidence interval (CI), 0.39-1.53, I2 = 26%) or case-control studies (pooled odds ratio, 0.99, 95% CI, 0.76-1.28, I2 = 31%). A 19% reduction in breast cancer risk (pooled RR: 0.81, 95% CI, 0.66-0.99, I2 = 72%) was found in the cohort studies. However, after removing the study with the smallest event number and the greatest effect size, the association became nonsignificant with greatly decreased heterogeneity (pooled RR: 0.94, 95% CI, 0.86-1.03, I2 = 16%). This meta-analysis did not find any significant association between TZDs use and risk of breast cancer among diabetic women.
AB - Rising experimental evidence suggests that thiazolidinediones (TZDs) exert a protective effect on breast cancer. However, studies concerning this issue were inconsistent and limited. Hence, we performed a meta-analysis with data from currently available studies to evaluate the effect of TZDs on breast cancer risk among diabetic women. We comprehensively searched for all pertinent studies addressing TZDs use and breast cancer risk published before January 1, 2016, in PubMed, Clinical Trials, and Cochrane Library. Data synthesis was performed in a random-effects model using Stata version 12.0 (Stata Corp, College Station, Texas). Fourteen independent studies were eventually selected in this meta-analysis, including 5 randomized controlled clinical trials (RCTs), 7 cohort studies, and 2 case-control studies. No significant associations of TZD use and risk of breast cancer were observed in the RCTs (pooled risk ratio [RR]: 0.77, 95% confidence interval (CI), 0.39-1.53, I2 = 26%) or case-control studies (pooled odds ratio, 0.99, 95% CI, 0.76-1.28, I2 = 31%). A 19% reduction in breast cancer risk (pooled RR: 0.81, 95% CI, 0.66-0.99, I2 = 72%) was found in the cohort studies. However, after removing the study with the smallest event number and the greatest effect size, the association became nonsignificant with greatly decreased heterogeneity (pooled RR: 0.94, 95% CI, 0.86-1.03, I2 = 16%). This meta-analysis did not find any significant association between TZDs use and risk of breast cancer among diabetic women.
KW - TZDs
KW - antidiabetic drugs
KW - breast cancer
KW - diabetes
KW - meta-analysis
KW - systematic review
UR - http://www.scopus.com/inward/record.url?scp=85038032763&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85038032763&partnerID=8YFLogxK
U2 - 10.1002/dmrr.2961
DO - 10.1002/dmrr.2961
M3 - Review article
C2 - 29125710
AN - SCOPUS:85038032763
SN - 1520-7552
VL - 34
JO - Diabetes/Metabolism Research and Reviews
JF - Diabetes/Metabolism Research and Reviews
IS - 2
M1 - e2961
ER -